2
|
Bremner KE, Mitsakakis N, Wilson L, Krahn MD. Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS). Prostate Cancer Prostatic Dis 2013; 17:47-56. [PMID: 24126796 DOI: 10.1038/pcan.2013.44] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2013] [Revised: 08/20/2013] [Accepted: 08/22/2013] [Indexed: 01/27/2023]
Abstract
BACKGROUND The Prostate Cancer Index (PCI) is a health profile instrument that measures health-related quality of life with six subscales: urinary, sexual, and bowel function and bother. The Patient-Oriented Prostate Utility Scale (PORPUS-U) measures utility (0=dead and 1=full health). Utility is a preference-based approach to measure health-related quality of life, required for decision analyses and cost-effectiveness analyses. We developed a function to estimate PORPUS-U utilities from PCI scores. METHODS The development data set included 676 community-dwelling prostate cancer (PC) survivors who completed the PCI and PORPUS-U by mail. We fit three linear regression models: one used original PORPUS-U scores and two used log-transformed PORPUS-U scores, one with a hierarchy constraint and one without. The model selection was performed using stepwise selection and fivefold cross validation. The validation data included 248 PC outpatients with three assessments on the PCI and PORPUS-U. Scores were retransformed for validation, with Duan's smearing estimator applied to correct potential bias. The predictive ability of the models was assessed with R(2), root mean square error (RMSE) and by comparing predicted and observed utilities. RESULTS The best-fitting model used the log-transformed PORPUS-U with no hierarchy constraint. The R(2) was 0.72. The RMSE ranged from 0.040 to 0.061 for the three validation data sets. Differences between predicted and observed utilities ranged from 0.000 to 0.006 but predicted utilities overestimated the lowest 5% of observed PORPUS-U scores and underestimated the highest observed scores. CONCLUSIONS Our algorithm can calculate PORPUS-U utility scores from PCI scores, thus supplementing descriptive quality of life measures with utility scores in PC patients. Utilities derived from mapping algorithms are useful for assigning utility to groups of patients but are less accurate at predicting utility of individual patients. We are exploring statistical methods to improve the mapping of utilities from descriptive instruments.
Collapse
Affiliation(s)
- K E Bremner
- 1] Toronto General Hospital, Clinical Decision Making and Health Care, University Health Network, Toronto, Ontario, Canada [2] Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, Ontario, Canada
| | - N Mitsakakis
- Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, Ontario, Canada
| | - L Wilson
- Faculty of Pharmacy, University of California San Francisco, San Francisco, CA, USA
| | - M D Krahn
- 1] Toronto General Hospital, Clinical Decision Making and Health Care, University Health Network, Toronto, Ontario, Canada [2] Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, Ontario, Canada [3] Department of Medicine, Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada [4] Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
4
|
Krahn MD, Bremner KE, Zagorski B, Alibhai SMH, Chen W, Tomlinson G, Mitsakakis N, Naglie G. Health care costs for state transition models in prostate cancer. Med Decis Making 2013; 34:366-78. [PMID: 23894082 DOI: 10.1177/0272989x13493970] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To obtain estimates of direct health care costs for prostate cancer (PC) from diagnosis to death to inform state transition models. METHODS A stratified random sample of PC patients residing in 3 geographically diverse regions of Ontario, Canada, and diagnosed in 1993-1994, 1997-1998, and 2001-2002, was selected from the Ontario Cancer Registry. We retrieved patients' pathology reports to identify referring physicians and contacted surviving patients and next of kin of deceased patients for informed consent. We reviewed clinic charts to obtain data required to allocate each patient's observation time to 11 PC-specific health states. We linked these data to health care administrative databases to calculate resource use and costs (Canadian dollars, 2008) per health state. A multivariable mixed-effects model determined predictors of costs. RESULTS The final sample numbered 829 patients. In the regression model, total direct costs increased with age, comorbidity, and Gleason score (all P < 0.0001). Radical prostatectomy was the most costly primary treatment health state ($4676 per 100 days). Radical prostatectomy, hormone-refractory metastatic disease ($6398 per 100 days), and final (predeath) ($13,739 per 100 days) health states were significantly more costly (P < 0.05) than nontreated nonmetastatic PC ($3440 per 100 days), whereas the postprostatectomy ($732 per 100 days) and postradiation ($1556 per 100 days) states cost significantly less (P < 0.0001). CONCLUSIONS This study used an innovative but labor-intensive approach linking chart and administrative data to estimate health care costs. Researchers should weigh the potential benefits of this method against what is involved in implementation. Modifications in methodology may achieve similar gains with less outlay in individual studies. However, we believe that this is a promising approach for researchers wishing to advance the quality of costing in state transition modeling.
Collapse
Affiliation(s)
- Murray D Krahn
- Department of Medicine, Toronto, ON, Canada (MDK, SMHA, GT, GN).,Faculty of Pharmacy, Toronto, ON, Canada (MDK),Institute of Health Policy, Management, and Evaluation, Toronto, ON, Canada (MDK, SMHA, GT, GN, BZ),Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, ON, Canada (MDK, SMHA, WC, GT, NM, GN, KEB),Toronto General Hospital, University Health Network, Toronto, ON, Canada (MDK, SMHA, GT, KEB),Institute for Clinical Evaluative Sciences, Toronto, ON, Canada (MDK, BZ)
| | - Karen E Bremner
- Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, ON, Canada (MDK, SMHA, WC, GT, NM, GN, KEB),Toronto General Hospital, University Health Network, Toronto, ON, Canada (MDK, SMHA, GT, KEB)
| | - Brandon Zagorski
- Institute of Health Policy, Management, and Evaluation, Toronto, ON, Canada (MDK, SMHA, GT, GN, BZ),Institute for Clinical Evaluative Sciences, Toronto, ON, Canada (MDK, BZ)
| | - Shabbir M H Alibhai
- Department of Medicine, Toronto, ON, Canada (MDK, SMHA, GT, GN).,Institute of Health Policy, Management, and Evaluation, Toronto, ON, Canada (MDK, SMHA, GT, GN, BZ),Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, ON, Canada (MDK, SMHA, WC, GT, NM, GN, KEB),Toronto General Hospital, University Health Network, Toronto, ON, Canada (MDK, SMHA, GT, KEB),Baycrest Geriatric Health Care System and Toronto Rehabilitation Institute, Toronto, ON,Canada (SMHA, GN)
| | - Wendong Chen
- Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, ON, Canada (MDK, SMHA, WC, GT, NM, GN, KEB)
| | - George Tomlinson
- Department of Medicine, Toronto, ON, Canada (MDK, SMHA, GT, GN).,Institute of Health Policy, Management, and Evaluation, Toronto, ON, Canada (MDK, SMHA, GT, GN, BZ),Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, ON, Canada (MDK, SMHA, WC, GT, NM, GN, KEB),Toronto General Hospital, University Health Network, Toronto, ON, Canada (MDK, SMHA, GT, KEB)
| | - Nicholas Mitsakakis
- Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, ON, Canada (MDK, SMHA, WC, GT, NM, GN, KEB)
| | - Gary Naglie
- Department of Medicine, Toronto, ON, Canada (MDK, SMHA, GT, GN).,Institute of Health Policy, Management, and Evaluation, Toronto, ON, Canada (MDK, SMHA, GT, GN, BZ),Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, ON, Canada (MDK, SMHA, WC, GT, NM, GN, KEB),Baycrest Geriatric Health Care System and Toronto Rehabilitation Institute, Toronto, ON,Canada (SMHA, GN)
| |
Collapse
|
6
|
Garg V, Shen X, Cheng Y, Nawarskas JJ, Raisch DW. Use of number needed to treat in cost-effectiveness analyses. Ann Pharmacother 2013; 47:380-7. [PMID: 23463742 DOI: 10.1345/aph.1r417] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
OBJECTIVE To review the use of number needed to treat (NNT) and/or number needed to harm (NNH) values to determine their relevance in helping clinicians evaluate cost-effectiveness analyses (CEAs). DATA SOURCES PubMed and EconLit were searched from 1966 to September 2012. STUDY SELECTION AND DATA EXTRACTION Reviews, editorials, non-English-language articles, and articles that did not report NNT/NNH or cost-effectiveness ratios were excluded. CEA studies reporting cost per life-year gained, per quality-adjusted life-year (QALY), or other cost per effectiveness measure were included. Full texts of all included articles were reviewed for study information, including type of journal, impact factor of the journal, focus of study, data source, publication year, how NNT/NNH values were reported, and outcome measures. DATA SYNTHESIS A total of 188 studies were initially identified, with 69 meeting our inclusion criteria. Most were published in clinician-practice-focused journals (78.3%) while 5.8% were in policy-focused journals, and 15.9% in health-economics-focused journals. The majority (72.4%) of the articles were published in high-impact journals (impact factor >3.0). Many articles focused on either disease treatment (40.5%) or disease prevention (40.5%). Forty-eight percent reported NNT as a part of the CEA ratio per event. Most (53.6%) articles used data from literature reviews, while 24.6% used data from randomized clinical trials, and 20.3% used data from observational studies. In addition, 10% of the studies implemented modeling to perform CEA. CONCLUSIONS CEA studies sometimes include NNT ratios. Although it has several limitations, clinicians often use NNT for decision-making, so including NNT information alongside CEA findings may help clinicians better understand and apply CEA results. Further research is needed to assess how NNT/NNH might meaningfully be incorporated into CEA publications.
Collapse
Affiliation(s)
- Vishvas Garg
- Pharmacoeconomics, Epidemiology, Pharmaceutical Policy, and Outcomes Research program, Department of Pharmacy Practice and Administrative Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM, USA.
| | | | | | | | | |
Collapse
|